Archives
-
Neuritin, NF-κB, and Early Brain Injury After SAH
2026-10-09
A 2024 Brain Research study links endoplasmic-reticulum-stress inflammatory pathways with neuroinflammation and neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Its central contribution is the evidence that neuritin overexpression may reduce these responses by suppressing several ER stress–NF-κB signaling branches, although the findings remain primarily preclinical and pathway-associative.
-
NSC 87877 and the SHP2 Neuroinflammation Frontier
2026-10-08
The SHP2/NLRP3 axis is emerging as a context-dependent regulator of neuroinflammation rather than a simple therapeutic switch. This article interprets recent tFUS stroke findings, evaluates NSC 87877 as a mechanistic Shp2 inhibitor, and outlines a translational evidence strategy without overstating preclinical results.
-
Neuritin, ER Stress, and Early Brain Injury After SAH
2026-10-07
The reference study connects neuritin with three endoplasmic-reticulum-stress pathways that converge on NF-κB during early brain injury after subarachnoid hemorrhage. Its findings support a mechanistic model in which neuritin overexpression reduces neuroinflammation and neuronal apoptosis, while also highlighting the need for pathway-specific validation and broader outcome testing.
-
Steroid Lysis of Protoplasts: Membrane Evidence
2026-10-07
Smith and Shay’s 1965 study used osmotically fragile Sarcina lutea protoplasts to separate direct membrane injury from effects mediated by the bacterial cell wall. Its protection and antagonism experiments supported a membrane-directed interpretation of synthetic steroid antimicrobial activity, while also showing why lysis assays require careful controls and limited claims.
-
ABT-263 (Navitoclax): Apoptosis Research Context
2026-10-06
A source-grounded overview of ABT-263 and Navitoclax in cancer biology, emphasizing BCL-2 family signaling, apoptosis research, the MDM1–TP53 chemoradiotherapy study, evidence strength, and translational limitations.
-
Naftifine HCl: Evidence, Context, and Limits
2026-10-06
Naftifine HCl is an allylamine antifungal agent described by the supplier as a squalene 2,3-epoxidase inhibitor for antifungal research. This overview separates that pharmacological context from findings in a supplied muscle-progenitor study, which offers conceptual insight into pathway analysis but provides no direct evidence for Naftifine HCl in WNT, GSK3, or skeletal-muscle models.
-
GSK3 Inhibition as Host-Directed TB Therapy
2026-10-05
The 2024 iScience study identifies glycogen synthase kinase 3 (GSK3) as a host pathway that can influence intracellular Mycobacterium tuberculosis growth. By combining pharmacological screening with genetic perturbation and phospho-proteomic analysis, the authors provide evidence for a host-directed treatment concept, while leaving questions about clinical translation, selectivity, and in vivo efficacy unresolved.
-
FLOT1–FOSL2–EphA2 Signaling in Alzheimer’s Disease
2026-10-05
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial activity through p38/MAPK signaling in APP/PS1 mice. The findings connect transcriptional regulation with neuroinflammation and cognitive outcomes, while remaining preclinical and model-dependent.
-
Vardenafil HCl Trihydrate: Evidence and Limits
2026-10-04
Vardenafil HCl Trihydrate is a selective PDE5 inhibitor research tool with a vendor-reported PDE5 IC50 of 0.7 nM in an in vitro enzymatic assay. Its tissue, animal-model, and native-proteoform evidence support distinct research questions, but they do not establish clinical efficacy or universal proteoform selectivity.
-
KR-12: Evidence, Mechanisms, and Research Context
2026-10-03
KR-12 is a compact LL-37-derived peptide studied for antimicrobial and host-response effects. Current evidence most clearly supports a Cu(II)-binding mechanism, while antibacterial, anti-biofilm, LPS-neutralizing, and tissue-related claims remain dependent on model, strain, and source quality.
-
Ibrexafungerp: Assay Workflows and Applications
2026-10-02
Ibrexafungerp, also known as MK 3118, supports resistance-aware Candida testing across neutral and acidic assay conditions. This practical guide translates pH activity data into reproducible susceptibility workflows, model-selection strategies, and troubleshooting steps for antifungal research.
-
Hyperthermia–Cisplatin Activates Caspase-8
2026-10-01
The reference study identifies caspase-8 accumulation and activation as a mechanistic link between hyperthermia–cisplatin treatment, apoptosis, and pyroptosis in cancer cells. Its combination of ubiquitination analysis, loss-of-function experiments, cell-death assays, and ultrastructural validation provides a framework for interpreting caspase-8 activity in combination-therapy research.
-
SARS-CoV-2 ORF3a Q57H and Apoptosis
2026-10-01
The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant can reduce pro-apoptotic signaling without substantially lowering total cellular ORF3a abundance. Its main contribution is to distinguish altered protein function and plasma-membrane distribution from simple loss of expression, providing a useful framework for dissecting viral control of host-cell death.
-
CCG-1423: A Practical RhoA Inhibitor Workflow
2026-09-30
CCG-1423 is a mechanistically focused RhoA inhibitor for connecting MRTF-A nuclear import with proliferation, invasion, apoptosis, and barrier-function phenotypes. This guide translates its use into reproducible cell-based workflows while clearly separating established product biology from exploratory applications in viral signaling.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-09-30
The reference study identifies Kupffer cell-expressed TMEM16F as a central determinant of host protection during Listeria monocytogenes infection. Cell-specific mouse models show that this calcium-activated lipid scramblase preserves macrophage membrane integrity, limits liver inflammation, and helps maintain metabolic homeostasis.